Direct Rap1-talin interaction in platelets, leukocytes, and endothelial cells
Rap1-talin 在血小板、白细胞和内皮细胞中的直接相互作用
基本信息
- 批准号:10676892
- 负责人:
- 金额:$ 48.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-05 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AchievementAdhesionsAgeAgonistAllelesBindingBinding SitesBiological AssayBloodBlood CellsBlood PlateletsBlood VesselsCarotid ArteriesCell AdhesionCell physiologyCellsCollaborationsCompensationDataDevelopmentDisabled PersonsEmbryoEndothelial CellsEndotheliumFoundationsHemorrhageHemostatic functionHomingIn VitroIndividualInflammationIntegrinsIntercellular JunctionsKnockout MiceLaser injuryLeukocytesLigandsLungLymphoid TissueMediatingMegakaryocytesModelingMolecular ConformationMusMutationNaturePathway interactionsPeripheralPhenotypePlayRoleSignal TransductionSiteStenosisStructureT-LymphocyteTalinTamoxifenTestingThrombosisTumor AngiogenesisVena caval structureVenous Thrombosisbrain endothelial cellcell typeferric chloridein vivomutantneutrophiloverexpressionplatelet functionrecruit
项目摘要
Abstract
Rap1 is a central signaling node connecting agonist stimulation to talin recruitment to integrins, a
final common step in integrin activation. In leukocytes, RIAM is a Rap1 effector that mediates
talin-dependent activation; however, in platelets the identity of such Rap1 effectors is obscure
and is a key gap in our understanding. Preliminary data suggest a new evolutionarily-conserved
paradigm that talin contains two Rap1 binding sites that enable it to serve as a Rap1 effector. The
applicant hypothesizes that talin itself is the principal, and perhaps only, Rap1 effector implicated
in platelet integrin activation. Secondly, he suggests that that the talin-Rap1 interaction may
contribute to integrin function even in leukocytes that contain an abundant Rap1 effector, RIAM
and in endothelial cells that contain substantial lamellipodin, a RIAM paralogue. To examine
these ideas: Specific Aim 1 will test the hypothesis that a direct Rap1-talin interaction plays
a central role in platelet integrin activation. Mice in which the megakaryocytes and platelets
express talin with either or both Rap1 binding sites disabled will be analyzed for platelet structure,
function, and formation. Hemostasis and thrombosis will be tested in a variety of assays. A
biomembrane force probe will characterize the role of the Rap1-talin interaction in individual
IIb3 integrin-ligand bonds. Specific Aim 2 will test the hypothesis that direct Rap1-Talin
interaction is important in RIAM-replete cells. In collaboration with Project 2 Integrin
activation, conformation, and topology in leukocytes will be analyzed in cells bearing each of the
three talin alleles described in Aim1. The effect of each mutation in combination with RIAM
deletion or with RIAM over-expression will test the relative roles of these two Rap1 effectors.
Specific Aim 3 will test the hypothesis that the talin-Rap1 interaction is important in
endothelial cells. Mice expressing one of the three mutant talin alleles selectively in
endothelium will be studied for hemorrhage and developmental phenotypes. Effects on integrin
activation, spreading, and cell-cell junctions will be assessed in vitro in primary lung and brain
microvascular endothelial cells. Lamellipodin deletion and over expression will enable an analysis
of the relationship of lamellipodin and Rap1 binding to talin in endothelial cell functions. Together,
achievement of these aims will test the paradigm-shifting hypothesis that talin itself serves as
the major Rap1 effector in platelet function in hemostasis and thrombosis and evaluate the
importance of the Rap1-talin interaction in leukocytes and endothelial cells.
摘要
Rap 1是连接激动剂刺激与talin募集至整合素的中枢信号节点,
整合素激活的最后一个共同步骤。在白细胞中,RIAM是一种Rap 1效应子,
talin依赖性激活;然而,在血小板中,这种Rap 1效应物的身份尚不清楚
这是我们认识上的一个关键空白。初步数据表明,一种新的进化保守的
范例,塔林包含两个Rap 1结合位点,使其能够作为Rap 1效应器。的
申请人假设talin本身是主要的,并且可能是唯一的,涉及Rap 1效应子
血小板整合素活化。其次,他认为talin-Rap 1相互作用可能
甚至在含有大量Rap 1效应子RIAM的白细胞中也有助于整合素功能
以及在含有大量片状脂质蛋白(一种RIAM蛋白)的内皮细胞中。审查
这些想法:具体目标1将测试Rap 1-talin直接相互作用的假设,
在血小板整合素活化中的核心作用。小鼠体内的巨核细胞和血小板
将分析Rap 1结合位点之一或两个都失活的表达talin的血小板结构,
功能和形成。将在各种试验中检测止血和血栓形成。一
生物膜力探针将表征Rap 1-talin相互作用在个体中的作用,
β IIb β 3整联蛋白-配体键。具体目标2将检验直接Rap 1-Talin
相互作用在RIAM充满的细胞中是重要的。与项目2集成合作
白细胞的活化、构象和拓扑结构将在携带每种
Aim 1中描述的三个talin等位基因。每种突变与RIAM组合的效果
缺失或RIAM过表达将测试这两个Rap 1效应子的相对作用。
具体目标3将检验talin-Rap 1相互作用在以下假设:
内皮细胞选择性表达三种突变talin等位基因之一的小鼠,
将研究内皮的出血和发育表型。对整合素的影响
将在体外评估原代肺和脑中的活化、扩散和细胞-细胞连接。
微血管内皮细胞板脂蛋白缺失和过表达将使分析成为可能。
的关系lamellipodin和Rap 1结合talin在内皮细胞功能。在一起,
这些目标的实现将检验塔林本身作为
血小板在止血和血栓形成中的主要Rap 1效应子,并评估
Rap 1-talin相互作用在白细胞和内皮细胞中的重要性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark HOWARD Ginsberg其他文献
Mark HOWARD Ginsberg的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark HOWARD Ginsberg', 18)}}的其他基金
Cellular Mechanisms of Inflammation, Hemostasis, and Thrombosis
炎症、止血和血栓形成的细胞机制
- 批准号:
10229365 - 财政年份:2020
- 资助金额:
$ 48.69万 - 项目类别:
Cellular Mechanisms of Inflammation, Hemostasis, and Thrombosis
炎症、止血和血栓形成的细胞机制
- 批准号:
10676869 - 财政年份:2020
- 资助金额:
$ 48.69万 - 项目类别:
Direct Rap1-talin interaction in platelets, leukocytes, and endothelial cells
Rap1-talin 在血小板、白细胞和内皮细胞中的直接相互作用
- 批准号:
10229368 - 财政年份:2020
- 资助金额:
$ 48.69万 - 项目类别:
Anti-Coagulant and Cytoprotective activity in CCM pathogenesis
CCM 发病机制中的抗凝血和细胞保护活性
- 批准号:
10417155 - 财政年份:2015
- 资助金额:
$ 48.69万 - 项目类别:
Anti-Coagulant and Cytoprotective activity in CCM pathogenesis
CCM 发病机制中的抗凝血和细胞保护活性
- 批准号:
10621253 - 财政年份:2015
- 资助金额:
$ 48.69万 - 项目类别:
Anti-Coagulant and Cytoprotective activity in CCM pathogenesis
CCM 发病机制中的抗凝血和细胞保护活性
- 批准号:
10220146 - 财政年份:2015
- 资助金额:
$ 48.69万 - 项目类别:
相似海外基金
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y004841/1 - 财政年份:2024
- 资助金额:
$ 48.69万 - 项目类别:
Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
- 批准号:
BB/Y001427/1 - 财政年份:2024
- 资助金额:
$ 48.69万 - 项目类别:
Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y005414/1 - 财政年份:2024
- 资助金额:
$ 48.69万 - 项目类别:
Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
- 批准号:
10669829 - 财政年份:2023
- 资助金额:
$ 48.69万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10587090 - 财政年份:2023
- 资助金额:
$ 48.69万 - 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
- 批准号:
10821599 - 财政年份:2023
- 资助金额:
$ 48.69万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10841832 - 财政年份:2023
- 资助金额:
$ 48.69万 - 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
- 批准号:
10532480 - 财政年份:2022
- 资助金额:
$ 48.69万 - 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
- 批准号:
10741261 - 财政年份:2022
- 资助金额:
$ 48.69万 - 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
- 批准号:
10674894 - 财政年份:2022
- 资助金额:
$ 48.69万 - 项目类别: